Citi Downgrades Acorda Therapeutics, Inc. (ACOR) to Neutral, Raises Price Target to $29
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Price: $0.66 --0%
Rating Summary:
4 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Citi downgraded shares of Acorda Therapeutics, Inc. (NASDAQ: ACOR) to a Neutral rating from its previous rating of Buy and raided its price target from $27 to $29.
For an analyst ratings summary and ratings history on Acorda Therapeutics, Inc. click here. For more ratings news on Acorda Therapeutics, Inc. click here.
Shares of Acorda Therapeutics, Inc. closed at $27.13 yesterday.
For an analyst ratings summary and ratings history on Acorda Therapeutics, Inc. click here. For more ratings news on Acorda Therapeutics, Inc. click here.
Shares of Acorda Therapeutics, Inc. closed at $27.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Desjardins Downgrades Alithya Group Inc. (ALYA:CN) (ALYA) to Hold
- JPMorgan Downgrades KinderCare Learning Companies (KLC) to Underweight
Create E-mail Alert Related Categories
DowngradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
